Advancing lentiviral vector manufacturing: flexibility, innovation, and readiness for the in vivo era

As a CDMO fully specialized in lentiviral vector (LVV) development and manufacturing, VIVEbiotech has spent the last decade building deep scientific, technical, and regulatory expertise—an effort recognized in 2025 with the CMO/CDMO of the Year Award at the Advanced Therapies Awards. Operating under FDA and EMA quality standards, the company supports more than 50 clients across the US, Europe, Asia, and Australia and has successfully produced over 180 bioreactor batches, with an annual capacity exceeding 60 GMP and non‑GMP runs.

One of the most significant industry shifts today is the rapid expansion of in‑vivo applications using lentiviral vectors, an area in which VIVEbiotech has become a reference due to its extensive hands‑on experience manufacturing clinical‑grade in‑vivo LVV batches.

The session will explore the current landscape of lentiviral vector manufacturing, the key trends shaping the in‑vivo field, and how flexible, high‑quality platforms enable developers to progress smoothly from early‑stage development to clinical and commercial manufacturing.